The global

Asthma and COPD Market

reached a valuation of USD 44.7 Billion in 2022 and is anticipated to achieve a value of USD 62.6 Billion by 2032, exhibiting a consistent revenue CAGR of 4.3% during the forecast period. This growth is primarily attributed to the increasing prevalence of respiratory ailments, escalating levels of air pollution, and enhancements in treatment options.


Respiratory conditions such as asthma and COPD disrupt the normal flow of air within the lungs, resulting in breathing difficulties. These maladies are becoming increasingly prevalent due to a multitude of factors, including factors like smoking, environmental air pollution, and genetic predisposition. According to data from the World Health Organization (WHO), there are approximately 339 million individuals worldwide suffering from asthma, and COPD is estimated to be responsible for approximately 3.17 million annual fatalities.


One of the pivotal driving forces behind the asthma and COPD market is the expanding prevalence of respiratory disorders. Governments and healthcare institutions worldwide are focusing on raising awareness about these conditions and providing improved healthcare services to patients. Furthermore, the rising utilization of medications such as inhaled corticosteroids, bronchodilators, and other therapeutics for the treatment of COPD and asthma is expected to further fuel the growth of market revenues.



Get a sample of the report @www.reportsanddata.com/download-free-sample/6912

Further key findings from the report suggest

  • Asthma and COPD are the two main illness types in the global respiratory industry, accounting for a sizeable portion of revenue in 2021, according to disease type insights. Based on the kind of ailment, the market has been divided into Asthma and COPD segments.
  • A group of medications known as bronchodilators aid in relaxing the muscles that surround the airways, making breathing easier. In 2021, a sizeable portion of revenue was attributable to this therapy type. The market for this kind of treatment is expanding as a result of rising elderly population, rising prevalence of respiratory disorders, and the accessibility of affordable and practical bronchodilators.
  • Millions of individuals globally suffer from asthma and COPD, two chronic respiratory conditions that place a heavy cost on healthcare systems. The global market for the treatment of COPD and asthma is expected to expand significantly during the forecast period due to a number of factors, including an ageing global population, an increase in smoking behaviours, and rising pollution levels.

  • In 2020, AstraZeneca plc announced that it had received approval from the US FDA for Breztri Aerosphere, a triple-combination therapy for the treatment of COPD. The approval was aimed at strengthening the company's product portfolio in the global COPD market.

Competitive Landscape:

  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Teijin Pharma Limited
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Asthma and COPD Market Report Scope

PARAMETERS DETAILS
The market size value in 2022 USD 44.7 Billion
CAGR (2022 - 2032) 4.3%
The Revenue forecast in 2032 USD 62.6 Billion
Base year for estimation 2022
Historical data 2020-2021
Forecast period 2022-2032
Quantitative units
  • Revenue in USD Billion
  • CAGR from 2022 to 2032
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered By Disease Type Outlook, Treatment Type Outlook, Mode of Administration Outlook, End-User Outlook, Regional Outlook
By Disease Type Outlook
By Treatment Type Outlook
  • Bronchodilators
  • Corticosteroids
  • Combination Inhalers
  • Others
By Mode of Administration Outlook
ByEnd-User Outlook
Regional scope North America; Europe; Asia Pacific; Latin America ; Middle East & Africa


Request a customization of the report @ www.reportsanddata.com/request-customization-form/6912

Explore Trending Reports:

Cardiac Monitoring Market -

www.reportsanddata.com/report-detail/cardiac-monitoring-market

Remote Patient Monitoring Market -

www.reportsanddata.com/report-detail/remote-patient-monitoring-market

Cancer Stem Cell Market -

www.reportsanddata.com/report-detail/cancer-stem-cells-market

Rapid Test Kit Market -

www.biospace.com/article/rapid-test-kit-market-size-2022-2030-integration-of-artificial-intelligence-ai-in-rapid-test-kits/

Antibody Production Market -

www.biospace.com/article/antibody-production-market-size-2022-2030-increased-demand-for-therapeutic-antibodies-is-driving-antibody-production-market-growth/

Cancer Biomarker Market -

www.biospace.com/article/cancer-biomarker-market-size-2022-2030-technological-advancements/

Drug Screening Market -

www.biospace.com/article/drug-screening-market-size-2022-2028-increasing-awareness-among-people-about-modern-testing-kits-and-improving-biochemical-industry-have-colossally-impacted-the-growth-of-the-market-curve/

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.



Contact Us:

John W

(Head of Business Development)


Reports and Data | Web:www.reportsanddata.com
Direct Line:

+1-212-710-1370


E-mail:[email protected]
Blogs

|

Press Release

|

Industry News

|

Our competencies
Browse MoreUpcoming Reports @www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @www.reportsanddata.com/report

COMTEX_441124534/2582/2023-09-28T05:41:53

Source link